Paul Hastings Advised Global Coordinators and Bookrunners in Connection with GenSight Biologics’ PIPE Financing
Paul Hastings LLP advised Chardan Capital Markets and Invest Securities as joint global coordinators and bookrunners in connection with GenSight Biologics’ private placement (PIPE). GenSight Biologics (Euronext: SIGHT) is a French biopharma company focused on developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders.
Partner Max Kirchner led the cross-border Paul Hastings team, which also included Co-head of Equity Capital Markets and Co-chair of the Corporate Life Sciences Group Seo Salimi and partner Charles Cardon.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.